Exco InTouch, a mobile messaging provider for the pharmaceutical industry, announces that its electronic patient reported outcomes (ePRO) solutions have been selected by Synairgen, a drug discovery company focused on asthma and chronic obstructive pulmonary disease (COPD).
Exco InTouch's Electronic Patient Diary Selected by Synairgen to Capture ePRO Data in IFN-beta Asthma Trial
(30 September, 2008) Exco InTouch, the leading mobile messaging provider for the pharmaceutical industry, announces that its electronic patient reported outcomes (ePRO) solutions have been selected by Synairgen, a drug discovery company focused on asthma and chronic obstructive pulmonary disease (COPD). Exco InTouch's short message service (SMS) ePRO offerings will enable Synairgen to collect patient data in its second clinical study of inhaled interferon beta (IFN-beta) for asthma treatment.
This Phase 1 study from Synairgen is designed to establish the safety of inhaled IFN-beta at four different dose levels over a 14 day period in asthmatic volunteers. Exco InTouch's innovative text messaging ePRO system will enable Synairgen to collect accurate PRO data which might be crucial in gauging the efficacy in future studies.
Using secure mobile online access, this technology will allow patients to complete diary questionnaires at pre-specified times via a series of text
messages. Secure text messages will enable Synairgen's patients to easily record and transmit data concerning their asthma using their own mobile phone, facilitating diary data collection which is then relayed back to the clinical sites for further analyses.
"Symptom diary cards are notoriously unreliable; we are attracted to this simple method for collecting asthma symptom scores on a daily basis," said Richard Marsden, Managing Director of Synairgen
About Exco InTouch's ePRO Solutions
For more complex data collection, a java application which runs on the patient's own mobile phone can be used in mobile data capture, dose titration and disease exacerbation monitoring. Simple and easy to deploy, Exco InTouch's software can be used for daily questionnaires in conjunction with the REACT compliance platform to deliver high quality data within appropriate timeframes.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.